Monday, October 07, 2024

Researchers identify new potential treatment for irregular heart rhythm

New research uncovers the regulatory mechanisms of the SK2 channel in heart function, paving the way for potential therapies targeting atrial fibrillation. 

A recent study by researchers at the University of Arizona College of Medicine - Phoenix and the University of California Davis Health discovered a new target for developing a medication to treat atrial fibrillation, the most prevalent kind of irregular heart rhythm. According to the US Centres for Disease Control and Prevention, atrial fibrillation, also known as AFib or AF, accounts for approximately one in every seven strokes and is associated with a considerable increase in morbidity and death. The American Heart Association predicts that more than 12 million people will have AFib by 2030, and existing treatment approaches are inadequate, according to researchers.

Proteins involved in physiological processes of the heart have been a target of research for AFib for some time. Until recently, most research suggested that treating AFib through inhibition of specific small-conductance calcium-activated potassium channels, or SK channels, could either reduce or worsen arrhythmias under different conditions.

Breakthrough in atrial fibrillation research

"Our study used pioneering experimental and computational approaches to decipher how the human SK2 channel can be dynamically co-regulated. The study is especially timely considering inhibitors of SK channels are currently in clinical trials to treat AFib, making further insight into their regulatory mechanisms paramount," said Nipavan Chiamvimonvat, MD, chair of the Department of Basic Medical Sciences at the U of A College of Medicine - Phoenix.

The paper, "Atomistic Mechanisms of the Regulation of Small Conductance Ca2 -Activated K channel (SK2) by PIP2," was published in the journal Proceedings of the National Academy of Sciences. The research team examined the role of a lipid - phosphatidylinositol 4,5-bisphosphate, or PIP2 - in regulating the SK2 channel. PIP2 is an integral component of all plant and animal cell membranes and acts as a messenger for a variety of signaling pathways in the body.

"Because PIP2 plays such an essential role in multiple ion channels, regulating cardiac ion channels through PIP2 presents a new mechanism for the lipid regulation of cardiac excitability and function," said computational biologist Ryan Woltz, PhD, the paper's co-first author and an assistant research professor at the College of Medicine - Phoenix. Currently, SK channels are the only known potassium channels that are upregulated in heart failure, and their regulation plays a critical role in cardiac excitability and how disturbances in the heart's rhythm develop.

"Since PIP2 is known to be dysregulated in heart failure, our study provides critical translational insights into possible mechanisms of cardiac arrhythmias in heart failure," said co-first author Yang Zheng, PhD, a postdoctoral research fellow at the College of Medicine - Phoenix. Using comparative modeling, the research team generated human SK2 channel models in closed, intermediate and open states. They then used molecular dynamics simulations to explore the molecular mechanisms of SK2 channel modulation by PIP2.

 

Labels: , , , ,

0 Comments:

Post a Comment

<< Home